

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(21) Application number: 87901672.3

(51) Int. Cl.: C 07 D 498/22, A 61 K 31/55

(22) Date of filing: 09.03.87

Data of the international application taken as a basis:

(86) International application number:
PCT/JP 87/00144

(87) International publication number:
WO 88/07045 (22.09.88 88/21)

(43) Date of publication of application: 22.02.89
Bulletin 89/8

(84) Designated Contracting States: DE FR GB

(71) Applicant: KYOWA HAKKO KOGYO CO., LTD., 6-1,
Ohtemachi 1-chome, Chiyoda-ku Tokyo 100 (JP)

(72) Inventor: MURAKATA, Chikara, 2-32-3, Narusedai
Machida-shi, Tokyo 194 (JP)
Inventor: SATO, Akira, 1880-30, Kiso-machi Machida-shi,
Tokyo 194 (JP)

(72) Inventor: TAKAHASHI, Mitsuru, 3-2-6-204, Mita Tama-ku,
Kawasaki-shi, Kanagawa 214 (JP)
Inventor: KOBAYASHI, Eiji, 2-11-21-706, Kurahara
Adachi-ku, Tokyo 123 (JP)
Inventor: MORIMOTO, Makoto, 1188, Shimotogari,
Nagaizumi-cho Sunto-gun, Shizuoka 411 (JP)
Inventor: AKINAGA, Shiro, 1188, Shimotogari
Nagaizumi-cho Sunto-gun, Shizuoka 411 (JP)
Inventor: HIRATA, Tadashi, 1566-315, Nara-cho
Midori-ku Yokohama-shi, Kanagawa 227 (JP)
Inventor: MOCHIDA, Kenichi, 325-5, Sanada
Hiratsuka-shi, Kanagawa 259-12 (JP)
Inventor: KASE, Hiroshi, 3-35-18, Maehara-cho
Koganei-shi, Tokyo 184 (JP)
Inventor: YAMADA, Koji, 1-12-2, Asahi-machi
Machida-shi, Tokyo 194 (JP)
Inventor: IWAHASHI, Kazuyuki, 3-17, Fujimidai
Kunitachi-shi, Tokyo 186 (JP)

(74) Representative: Lambert, Hugh Richmond et al, D.
YOUNG & CO. 10 Staple Inn, London, WC1V 7RD (GB)

(54) DERIVATIVES OF PHYSIOLOGICALLY ACTIVE SUBSTANCE K-252.

(57) Novel derivatives of K-252 ((8R*, 9S*, 11S*)-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo[a,g]cycloocta[cde]trinden-1-one) represented by formula (I) (wherein W, Ws, R¹, R², R³, R⁴, X, and Y represent various substituents) are disclosed. These compounds are physiologically active substances having a protein kinase C-inhibiting activity and an oncostatic activity, thus being useful as medicines.

EP 0 303 697 A1

BEST AVAILABLE COPY

Isolation and purification of the product after completion of each step described above can be carried out by methods used in conventional organic synthesis, for example, by an appropriate combination of extraction, crystallization, chromatography, etc.

Compound (I) shows a marked cell growth inhibitory activity against human uterine cervical cancer HeLa cells, human breast cancer cell MCF 7, human colon adenocarcinoma cell COLO320DM and human lung differentiated squamous cell carcinoma cell PC-10, and accordingly, anti-tumor compositions comprising Compound (I) as an effective ingredient are provided.

Compound (I) and its pharmacologically acceptable salts include oleophilic and hydrophilic ones and such properties are particularly preferred for pharmaceutical use in some cases. In cases where Compound (I) is used as an anti-tumor composition, each compound is dissolved in physiological saline or a solution of glucose, lactose or mannitol for injection, and usually intravenously administered as an injection in a dose of 0.01 to 20 mg/kg. Alternatively, the compound may be freeze-dried in accordance with the Japanese Pharmacopoeia or may be prepared into injectable powder by adding sodium chloride thereto. Further, the anti-tumor composition may also contain pharmacologically acceptable well-known diluents, adjuvants and/or carriers such as salts which satisfy requirements for medical use. In cases where the compound is used as an injection, it is sometimes preferred to use auxiliary agents which enhance the solubility. Doses may be appropriately varied depending upon the age and conditions. Administration schedule can also be varied depending upon the conditions and dose. For example, the compound is administered once a day (by single administration or consecutive administration) or intermittently one to three times a week or once every three weeks. Further, oral administration and rectal administration are also possible in the same dose and in the same manner.

The compound can be administered, with appropriate adjuvants, as tablets, powders, granules, syrup, etc. for oral administration and as suppositories for rectal administration.

5. Examples

Representative examples of Compound (I) obtained by the processes described above are shown in Table 2 and the intermediates thereof are shown in Table 3.

Examples of preparation of the Compound (I) and the intermediates are respectively shown in Examples and
10 Reference Examples. Compound Nos. correspond to Example
Nos.

15


20

25




30

35

Table 2



Com- pound No.	R ¹	R ²	R ³	R ⁴	W ₁ W ₂	X	Y
1	H	H	H	H	H	CONHOH	OH
2	H	H	H	H	H	CONH ₂	OH
3	H	H	H	H	H	CONHCH ₂ CH ₂ OH	OH
4	H	H	H	H	H	CO ₂ Et	OH
5	H	H	H	Cl	H	CO ₂ Me	OH
6	Cl	H	H	H	H	CO ₂ Me	OH
7	Br	H	H	H	H	CO ₂ Me	OH
8	H	H	H	CONH ₂	H	CO ₂ Me	OH
9	NH ₂	H	H	H	H	CO ₂ Me	OH
10	NH ₂	H	NH ₂	H	H	CO ₂ Me	OH
11	H	NH ₂	H	H	H	CO ₂ Me	OH
12	NMe ₂	H	H	H	H	CO ₂ Me	OH
13	NHCONHMe	H	H	H	H	CO ₂ Me	OH
14	NHCONH ₂	H	H	H	H	CO ₂ Me	OH
15	OH	H	H	H	H	CO ₂ Me	OH
16	OH	H	OH	H	H	CO ₂ Me	OH

Compound No.	R ¹	R ²	R ³	R ⁴	W ₁ W ₂	X	Y
17	On-Pr	H	H	H	H	CO ₂ Me	OH
18	CH ₂ OH	H	H	H	H	CO ₂ Me	OH
19	Me	H	H	H	H	CO ₂ Me	OH
20	H	H	H	H	H	CH ₂ OH	OH
21	OH	H	H	H	H	CH ₂ OH	OH
22	Cl	H	H	H	H	CH ₂ OH	OH
23	NH ₂	H	H	H	H	CH ₂ OH	OH
24	Br	H	H	H	H	CH ₂ OH	OH
25	OH	H	OH	H	H	CH ₂ OH	OH
26	Me	H	H	H	H	CH ₂ OH	OH
27	H	H	H	H	H	CH ₂ OCOCH ₂ CH ₂ CO ₂ H	OH
28 *)	H	H	H	H	H	CH ₂ O- 	OH
29	H	H	H	H	H	CH ₂ N ₃	OH
30	H	H	H	H	H	CH ₂ NH ₂	OH
31	H	H	H	H	H	CH ₂ NHCH ₂ CO ₂ Me	OH
32	H	H	H	H	H	CH ₂ NHCH ₂ CO ₂ H	OH
33	H	H	H	H	H	CH ₂ N = CH-NMe ₂	OH
34	H	H	H	H	H	CH ₂ NHCOCH ₂ NH ₂	OH
35	H	H	H	H	H	CH ₂ NHCO- 	OH
36	H	H	H	H	H	-CH ₂ O-	
37	H	H	H	H	H	CH ₂ NHMe	OH
38	H	H	H	H	H	CH ₂ N- 	OH